Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients

British Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2009, Pages 891-897

  Pereira, S A ^a   Batuca, J R ^a   Caixas, U ^a,b   Branco, T ^c   Delgado Alves, J ^a   Germano, I ^b   Lampreia, F ^b   Monteiro, E C ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b Centro Hospitalar de Lisboa Zona Central ^*  (Portugal)

^c HOSPITAL FERNANDO FONSECA   (Portugal)

Author keywords

Antiretrovirals; Efavirenz; HDL antioxidant function; High density lipoprotein function; HIV; Paraoxonase activity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BEDTIME DOSAGE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPID BLOOD LEVEL; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT DURATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-RETROVIRAL AGENTS; ARYLDIALKYLPHOSPHATASE; BENZOXAZINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; STATISTICS AS TOPIC;

EID: 70849134696     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03535.x     Document Type: Article

References (37)

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigator. N Engl J Med 1998 338 : 853 60.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000 356 : 1423 30.
3. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999 13 : F63 70.
4. Negredo E, Ribalta J, Ferre R, Salazar J, Rey-Joly C, Sirera G, Masana L, Clotet B. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004 18 : 819 21.
5. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004 1 : 64 73.
6. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005 19 : 917 25.
7. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003 289 : 2978 82.
8. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008 199 : 79 86.
9. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001 98 : 13925 30.
10. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006 1 : e365.
11. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989 79 : 8 15.
12. Alonso-Villaverde C, Segues T, Coll-Crespo B, Pérez-Bernalte R, Rabassa A, Gomila M, Parra S, Gozález-Esteban MA, Jiménez- Expósito MJ, Masana L. High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. AIDS 2003 17 : 1173 8.
13. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favourably affected by simvastatin treatment. Circulation 2003 108 : 2751 6.
14. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997 99 : 2005 19.
15. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008 299 : 1265.
16. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Arteriosclerosis 1993 104 : 129 35.
17. Gil L, Martínez G, González I, Tarinas A, Alvarez A, Giuliani A, Molina R, Tápanes R, Pérez J, León OS. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res 2003 47 : 217 24.
18. Ngondi JL, Oben J, Forkah DM, Etame LH, Mbanya D. The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther 2006 22 : 3 19.
19. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 2007 29 : 1448 55.
20. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, Mackness M, Mackness B, Masana L, Joven J, Camps J. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007 194 : 175 81.
21. Pereira SA, Branco T, Côrte-Real RM, Germano I, Lampreia F, Caixas U, Monteiro EC. Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. Br J Clin Pharmacol 2006 61 : 601 4.
22. Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann NY Acad Sci 2007 1108 : 137 46.
23. Pereira SA, Branco T, Caixas U, Côrte-Real RM, Germano I, Lampreia F, Monteiro EC. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. Ther Drug Monit 2008 30 : 60 6.
24. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003 107 : 2775 9.
25. Ferré N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, Coll B, Tous M, Joven J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006 45 : 51 9.
26. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004 37 : 1986 94.
27. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI WISE Study Group. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003 72 : 13 22.
28. Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, Bontempo F, Kammerer C, Kamboh MI. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006 54 : 1928 39.
29. Thyagarajan B, Jacobs DR Jr., Carr JJ, Alozie O, Steffes MW, Kailash P, Hayes JH, Gross MD. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2008 54 : 738 46.
30. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004 15 : 399 404.
31. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999 9 : 745 53.
32. Playfer JR, Eze LC, Bullen MF, Evans DA. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J Med Genet 1976 13 : 337 42.
33. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Eur J Clin Invest 1998 12 : 1653 9.
34. Sandstrom PA, Murray J, Folks TM, Diamond AM. Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. Free Radic Biol Med 1998 24 : 1485 91.
35. Treitinger A, Spada C, Verdi JC, Miranda AF, Oliveira OV, Silveira MV, Moriel P, Abdalla DS. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Invest 2000 5 : 454 9.
36. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001 15 : 2407 14.
37. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009 46 : 83 106.